Morgan Stanley
ASMB icon

Morgan Stanley’s Assembly Biosciences ASMB Stock Holding History

Morgan Stanley’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$917K Buy
33,055
+10,521
+47% +$300K ﹤0.01% 5188
2025
Q4 		$766K Buy
22,534
+19,007
+539% +$612K ﹤0.01% 5312
2025
Q3 		$90.3K Buy
3,527
+1,378
+64% +$30.2K ﹤0.01% 6197
2025
Q2 		$38.9K Sell
2,149
-151
-7% -$1.99K ﹤0.01% 6437
2025
Q1 		$22K Sell
2,300
-686
-23% -$8.97K ﹤0.01% 6539
2024
Q4 		$47.1K Buy
2,986
+326
+12% +$5.25K ﹤0.01% 6304
2024
Q3 		$40.3K Buy
2,660
+98
+4% +$1.49K ﹤0.01% 6277
2024
Q2 		$35.2K Buy
2,562
+90
+4% +$1.28K ﹤0.01% 6280
2024
Q1 		$32.9K Sell
2,472
-2,638
-52% -$30.7K ﹤0.01% 6356
2023
Q4 		$50.3K Buy
5,110
+1,383
+37% +$13.1K ﹤0.01% 6383
2023
Q3 		$39.6K Sell
3,727
-6
-0.2% -$72 ﹤0.01% 6264
2023
Q2 		$51.5K Buy
3,733
+31
+0.8% +$381 ﹤0.01% 6200
2023
Q1 		$37.3K Buy
3,702
+1,087
+42% +$18.3K ﹤0.01% 6390
2022
Q4 		$40.8K Sell
2,615
-1,947
-43% -$33.3K ﹤0.01% 6378
2022
Q3 		$89K Sell
4,562
-1,127
-20% -$27.3K ﹤0.01% 6138
2022
Q2 		$143K Buy
5,689
+211
+4% +$4.86K ﹤0.01% 6073
2022
Q1 		$135K Sell
5,478
-35
-0.6% -$751 ﹤0.01% 6134
2021
Q4 		$155K Buy
5,513
+764
+16% +$25K ﹤0.01% 6190
2021
Q3 		$198K Sell
4,749
-3,951
-45% -$166K ﹤0.01% 6003
2021
Q2 		$405K Buy
8,700
+7,970
+1,092% +$395K ﹤0.01% 5657
2021
Q1 		$40K Sell
730
-34,753
-98% -$2.3M ﹤0.01% 6445
2020
Q4 		$2.58M Buy
35,483
+3,400
+11% +$399K ﹤0.01% 3932
2020
Q3 		$6.33M Buy
32,083
+30,815
+2,430% +$7.76M ﹤0.01% 2486
2020
Q2 		$354K Sell
1,268
-12,070
-90% -$2.82M ﹤0.01% 4783
2020
Q1 		$2.37M Buy
13,338
+8,383
+169% +$1.8M ﹤0.01% 3215
2019
Q4 		$1.22M Sell
4,955
-9,392
-65% -$1.73M ﹤0.01% 4398
2019
Q3 		$1.69M Sell
14,347
-3,173
-18% -$480K ﹤0.01% 3930
2019
Q2 		$2.83M Buy
17,520
+7,507
+75% +$1.43M ﹤0.01% 3483
2019
Q1 		$2.37M Buy
10,013
+6,847
+216% +$1.73M ﹤0.01% 3449
2018
Q4 		$859K Sell
3,166
-3,236
-51% -$936K ﹤0.01% 4391
2018
Q3 		$2.85M Buy
6,402
+776
+14% +$363K ﹤0.01% 3708
2018
Q2 		$2.65M Buy
5,626
+2,481
+79% +$1.31M ﹤0.01% 3816
2018
Q1 		$1.85M Buy
3,145
+195
+7% +$121K ﹤0.01% 4076
2017
Q4 		$1.6M Sell
2,950
-214
-7% -$96.9K ﹤0.01% 4211
2017
Q3 		$1.33M Buy
3,164
+930
+42% +$285K ﹤0.01% 4232
2017
Q2 		$554K Buy
2,234
+347
+18% +$97.7K ﹤0.01% 4735
2017
Q1 		$577K Buy
1,887
+1,355
+255% +$332K ﹤0.01% 4750
2016
Q4 		$78K Sell
532
-139
-21% -$20.7K ﹤0.01% 5644
2016
Q3 		$58K Buy
671
+284
+73% +$21.9K ﹤0.01% 5524
2016
Q2 		$26K Buy
387
+84
+28% +$5.51K ﹤0.01% 5760
2016
Q1 		$19K Sell
303
-24
-7% -$1.6K ﹤0.01% 5928
2015
Q4 		$29K Sell
327
-4,923
-94% -$536K ﹤0.01% 5913
2015
Q3 		$603K Buy
5,250
+4,262
+431% +$750K ﹤0.01% 4489
2015
Q2 		$228K Sell
988
-1,562
-61% -$301K ﹤0.01% 5167
2015
Q1 		$405K Buy
2,550
+149
+6% +$20.2K ﹤0.01% 4790
2014
Q4 		$227K Buy
2,401
+934
+64% +$92K ﹤0.01% 5175
2014
Q3 		$144K Buy
1,467
+1,440
+5,333% +$128K ﹤0.01% 5308
2014
Q2 		$2K Sell
27
-516
-95% -$36.6K ﹤0.01% 6382
2014
Q1 		$42K Buy
543
+16
+3% +$2.49K ﹤0.01% 5771
2013
Q4 		$121K Sell
527
-27
-5% -$4.92K ﹤0.01% 5271
2013
Q3 		$96K Sell
554
-166
-23% -$25.4K ﹤0.01% 5097
2013
Q2 		$103K Buy
+720
New +$113K ﹤0.01% 5064

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Morgan Stanley's ASMB Position: Q1 2026 in Review

Morgan Stanley increased its Assembly Biosciences (ASMB) stake by 47% in Q1 2026, buying an estimated $300K and bringing the position to 33,055 shares worth $917K. The position accounts for ﹤0.01% of the portfolio, ranked #5188.

Morgan Stanley first reported a position in ASMB in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.33M in Q3 2020. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Morgan Stanley held 33,055 shares of Assembly Biosciences worth $917K as of Q1 2026.
  • Morgan Stanley bought 10,521 Assembly Biosciences shares in Q1 2026, an estimated $300K.
  • Assembly Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5188 holding.
  • Morgan Stanley first reported a position in Assembly Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Morgan Stanley's Assembly Biosciences position peaked at $6.33M in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.